Abstract

Acne Vulgaris: Management , published on 25 June 2021, is a National Institute for Health and Care Excellence (NICE) guideline for patients with acne, their families and carers, their healthcare professionals, and commissioners.1 It does not consider neonatal acne. This article highlights parts of the guideline that cover skin care advice and first-line medication options in the management of acne. The guideline also covers further areas such as ‘Referral to specialist care’, ‘Oral isotretinoin’, Physical treatment’, ‘Relapse’, Maintenance treatment’, and ‘Management of acne-related scarring’, which will not be covered in this article. Acne vulgaris is one of the commonest inflammatory skin conditions, reported to create 3.5 million general practice consultations per year in the UK.2 It usually affects adolescents and young adults, and can last for several years. Acne vulgaris most commonly affects the face but chest, back, and shoulders may be involved. Lesions are a combination of non-inflammatory (comedones) and inflammatory lesions (papules, pustules, cysts, nodules), often leading to scarring. The committee agreed to grade acne vulgaris into ‘Mild to Moderate’ or ‘Moderate to Severe’ in order to conduct separate network meta-analysis, while accepting that acne lies along a continuum. This is easily accomplished in busy clinics and provides a baseline for assessing treatment response. Mild-to-moderate acne vulgaris includes patients who have one or more of:

Highlights

  • Acne Vulgaris: Management, published on 25 June 2021, is a National Institute for Health and Care Excellence (NICE) guideline for patients with acne, their families and carers, their healthcare professionals, and commissioners.[1]

  • The committee agreed to grade acne vulgaris into ‘Mild to Moderate’ or ‘Moderate to Severe’ in order to conduct separate network meta-analysis, while accepting that acne lies along a continuum

  • This guideline provides a variety of options for primary care clinicians to consider when discussing management with patients with acne vulgaris

Read more

Summary

Clinical Practice

New NICE guidance on acne vulgaris: implications for first-line management in primary care. J Wilcock, MA HEd, FRCGP, PGCMed Ed, GP, Silverdale Medical Practice, Swinton, Manchester. L Kuznetsov, PhD, systematic reviewer, National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, London. J Ravenscroft, MRCP, consultant dermatologist and honorary consultant lecturer, Queen's Medical Centre, Nottingham. MI Rafiq, MPharm, pharmacist and independent prescriber, Pembroke Surgery, Reading. E Healy, PhD, FRCP, professor of dermatology, University of Southampton, Southampton, and Honorary Consultant Dermatologist, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton

INTRODUCTION
Acne severity Treatment
Mild to moderate
WHAT ARE THE OPTIONS FOR STARTING TREATMENT?
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call